Sudeep Pharma Q2 FY27 Share Price & Earnings Call Analysis

Part of: Nifty Microcap 250 · Nifty Total Market

₹1,210.30-0.14% today
Market cap
₹13,666 Cr
P/E
72.56
ROE
25.17%
PEG
1.80
Price to sales
19.25
Debt to equity
0.20
52W high / low
₹1,344 / ₹530
Sales growth (5Y)
24.45%
EBITDA margin
35.33%
Net profit margin
27.14%
Promoter holding
76.16%
Sales (last year)
₹710 Cr

Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.[1]

Guidance scorecard · Q2 FY27 call

What Sudeep Pharma's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#24of 86 in
Pharmaceuticals & Biotechnology

RevenueQ2 FY27 call

20–40%
  • NSS will have a flattish year in FY27 with no significant growth; growth expected from FY28 supported by 5 secured customer approvals.
  • NSS revenue in FY28 is targeted to grow at a pace similar to Sudeep's core business growth today.
  • Battery materials commercial supply expected to start by FY28 with ~15-20% utilization initially, ramping to 75% over 3-4 years.
  • Specialty Ingredients expected to return to positive year-on-year growth in Q3 and Q4 FY27 driven by new customer contracts despite fortified rice program pause.
  • PFN business shows strong growth with core products operating near 80% utilization; greenfield plant to start adding volumes from Q4 FY27.

2 more points from Sudeep Pharma's call on revenue

Create a free account to keep reading this call

Full Q2 FY27 analysis

MarginsQ2 FY27 call

Flat

See what Sudeep Pharma said on margins — free account, 30 seconds.

Full Q2 FY27 analysis

CapexQ2 FY27 call

Planned
  • FY27 capex was about INR77 crores, mainly towards the Battery Materials project at Dahej and completion of the greenfield facility.
  • Future capex for Battery Materials Phase 2 will be based on binding contracts expected to be signed in Q4 FY27, enabling scale-up beyond initial 100,000 tons capacity.
  • Greenfield facility at Dahej has recently received approval; utilization expected to start increasing from Q3 FY27 with meaningful scale from Q4 FY27.

2 more points from Sudeep Pharma's call on capex

Create a free account to keep reading this call

Full Q2 FY27 analysis

FundraisingQ2 FY27 call

See what Sudeep Pharma said on fundraising — free account, 30 seconds.

Full Q2 FY27 analysis

Order bookQ2 FY27 call

  • For the Battery Materials business (iron phosphate), the company expects to sign binding commitments in Q4 FY27, before commissioning Phase 1 in April 2027.
  • Strong visibility and offtake agreements exist not only for Phase 1 capacity of 25,000 tons but also for planned expansions up to 100,000 and 200,000 tons.
  • Exact volume details of binding contracts versus those under negotiation will be shared in the next quarter.
  • NSS (presumably a business segment) will have a flattish year in FY27 without significant growth but expects growth supported by 5 customer approvals in FY28 and FY29.
  • NSS aims for ~30% EBITDA margin in FY28 post supply chain optimization.
  • The greenfield facility has just begun operations, so volumes may gradually ramp up starting Q4 FY27.

2 more points from Sudeep Pharma's call on the order book

Create a free account to keep reading this call

Full Q2 FY27 analysis

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. 1
  3. 3

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹3,041 Cr33.1
240%+Up 2%+₹492 Cr19.6
340%+Up 0–2%₹234 Cr17.8
440%+Flat₹18,347 Cr—
540%+Flat₹8,432 Cr32.4
640%+Flat₹4,295 Cr—

Financials of Sudeep Pharma

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Sudeep Pharma

Shareholding breakup across reporting periods.

Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +76.16%76.16%76.16%76.16%
FIIs +1.67%1.55%1.81%2.93%
DIIs +17.59%18.11%15.64%14.06%
Public +4.57%4.18%6.39%6.87%
No. of Shareholders43,59936,50335,69540,465

Financials of Sudeep Pharma

Quarterly Results

Quarter-by-quarter operating performance

Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +149116158125163172182158197
YoY Sales growth+9%+49%+16%+27%+21%
Expenses +85769981107112120103123
Operating Profit633959445560635573
OPM %43%34%37%35%34%35%34%35%37%
Other Income +2245107656
Interest112221223
Depreciation333344445
Profit before tax623858446062635471
Tax %21%24%24%29%21%23%23%25%27%
Net Profit +492944314748494152
EPS in Rs5.802.954.543.174.714.204.333.594.56

Financials of Sudeep Pharma

Profit & Loss

Annual income statement trend

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +123215343429459502642710
Sales growth+75%+59%+25%+7%+9%+28%+27%
Expenses +98171276338276310419459
Operating Profit25446790183192223251
OPM %21%20%20%21%40%38%35%35%
Other Income +3379692825
Interest11265788
Depreciation34589111517
Profit before tax25436986175183228250
Tax %27%22%27%28%24%24%24%
Net Profit +18335062133139174189
EPS in Rs2.153.975.977.4215.8614.2715.3116.68
Dividend Payout %0%0%0%0%0%0%0%

Financials of Sudeep Pharma

Balance Sheet

Capital structure and asset base

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital11111101111
Reserves80113162222355481872946
Borrowings +2031848378140150189
Other Liabilities +3067971138086141182
Total Liabilities1312133444205147171,1741,329
Fixed Assets +6068137158180189337524
CWIP824826458818554
Investments619030000
Other Assets +57102199232289439652751
Total Assets1312133444205147171,1741,329

Financials of Sudeep Pharma

Cash Flows

Operating, investing and financing cash movement

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +1035-348664970
Cash from Investing Activity +-22-40-38-50-49-79-327
Cash from Financing Activity +121351-10-1353247
Net Cash Flow-0810-11423-10
Free Cash Flow124-77113-15-49
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit62%104%22%78%60%47%56%

Financials of Sudeep Pharma

Ratios

Working capital efficiency and return ratios

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days909411480115135129
Inventory Days7779104142147309356
Days Payable70797677112145113
Cash Conversion Cycle9793142145150298372
Working Capital Days4613309299144175
ROCE %36%36%33%49%36%28%

Guidance history

How Sudeep Pharma's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q2 FY27 call →20–40%FlatPlanned——
Q1 FY27 call →20–40%FlatPlanned—Rising
Q4 FY26 call →10–20%FlatPlanned—Rising
Q3 FY26 call →20–40%FlatPlanned—Rising

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

Others in Pharmaceuticals & Biotechnology this season

  • Divis Laboratories (Q2 FY27)

    Consolidated total income: ₹3770 crores . Key results statement takeaways from Divis Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sec

  • Infinium Pharma (Q2 FY27)

    3,940.98 Lacs (about 54.3% increase) . Key results statement takeaways from Infinium Pharmachem Ltd's Q2 FY27 results statement — and how it ranks against secto

  • Walpar Nutrition (Q2 FY27)

    3,631.14 Lakhs for the half year ended September 30, 2025, reflecting a year-on-year increase of approximately 13.79%. Key results statement takeaways from Walp

  • Kilitch Drugs (Q2 FY27)

    14.3%) . Key results statement takeaways from Kilitch Drugs (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.